Enlivex Therapeutics

Company Overview

Snapshot

Founded in September 2005 by Prof. Dror Mevorach, Enlivex Therapeutics operates with 11–50 employees. The company has raised $286.9M across 11 funding rounds from 5 investors. In November 2025, Enlivex Therapeutics raised $212M in a PIPE funding round.

Business overview

Enlivex Therapeutics is a clinical-stage company specializing in macrophage reprogramming cell therapies. The company focuses on developing and commercializing a drug pipeline aimed at macrophage reprogramming for various life-threatening diseases, including solid cancers, sepsis, and COVID-19. Its flagship product candidate, Allocetra, is designed to reprogram diseased macrophages and has shown positive safety, tolerability, and efficacy in clinical trials for sepsis and COVID-19 patients. Enlivex operates within the Health Tech & Life Sciences sector, specifically in Pharmaceuticals and Drugs Discovery & Development, serving healthcare providers and patients globally.

Strategic signal

In November 2025, Enlivex Therapeutics announced a significant $212 million PIPE funding round, coupled with the appointment of former Italian Prime Minister Matteo Renzi to its board of directors. This substantial capital injection and high-profile board addition signal strong investor confidence and strategic intent to accelerate the company's clinical development and market expansion, particularly following positive 6-month topline data demonstrating durable pain reduction and improved function in patients with moderate to severe knee osteoarthritis.

Company Intelligence Q&A

What was a significant recent funding event for Enlivex Therapeutics?

In November 2025, Enlivex Therapeutics raised $212 million in a PIPE funding round. This substantial capital injection was announced alongside the appointment of former Italian Prime Minister Matteo Renzi to its board of directors, signaling strong investor confidence and strategic intent to accelerate the company's clinical development and market expansion.

What was a key strategic development for Enlivex Therapeutics in November 2025?

In November 2025, Enlivex Therapeutics appointed Mr. Matteo Renzi, former Prime Minister of Italy, to its board of directors, signaling a strengthening of its strategic leadership.

What recent clinical data did Enlivex Therapeutics announce regarding Allocetra?

In November 2025, Enlivex Therapeutics announced positive 6-month topline data for Allocetra, demonstrating durable and persistent pain reduction and improved function in primary age-related patients with moderate to severe knee osteoarthritis.

What regulatory authorization did Enlivex Therapeutics receive in September 2024?

In September 2024, Enlivex Therapeutics received authorization from the Danish Medicines Agency to initiate the Phase II stage of its Phase I/II trial of Allocetra in patients with moderate to severe knee osteoarthritis.

When did Enlivex Therapeutics receive a notice of allowance for a Japanese patent application?

In October 2024, Enlivex Therapeutics received a notice of allowance for a Japanese patent application covering the use of Allocetra in patients with osteoarthritis.